{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062109","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.939215+00:00","generated_at":"2026-06-08T06:51:40.646646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"4DMT Q3 2023 net loss narrows to $10.3M; cash $320M, runway into H1 2026; clinical progress across pipeline","bullets":["Net loss of $10.3M versus $25.7M in Q3 2022; decrease primarily due to $20M upfront from Astellas License Agreement.","Cash, cash equivalents and marketable securities $320M as of Sep 30, 2023, up from $218M at Dec 31, 2022; runway into first half of 2026.","Completed enrollment of 4D-150 PRISM Phase 2 Dose Expansion for wet AMD nearly two quarters ahead of schedule; interim data expected early 2024.","Received EMA PRIME designation for 4D-150; reached agreement with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.","R&D expenses rose to $25.1M from $18.9M driven by clinical trial progression and higher headcount; G&A expenses $9.1M versus $8.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062109","json":"https://secwatch.observer/filing/0000950170-23-062109.json","markdown":"https://secwatch.observer/filing/0000950170-23-062109.md","text":"https://secwatch.observer/filing/0000950170-23-062109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/0000950170-23-062109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/fdmt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:51:40.646646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56c93bd2f65e860ccc91729a48317e7a6042d3a9","claim":"4D Molecular Therapeutics, Inc. reported financial results for the three months ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/0000950170-23-062109-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}